Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Paper biosensors for detecting elevated IL-6 levels in blood and respiratory samples from COVID-19 patients

Cristina Adrover-Jaume, Alejandra Alba-Patiño, Antonio Clemente, Giulia Santopolo, Andreu Vaquer, Steven M. Russell, Enrique Barón, María del Mar González del Campo, Joana M. Ferrer, María Berman-Riu, Mercedes García-Gasalla, María Aranda, Marcio Borges, Roberto de la Rica

1 Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), Son Espases University Hospital, 07120, Palma de Mallorca, Spain
2 University of the Balearic Islands, Chemistry Department, Cra. de Valldemossa km 7,5, 07122, Palma de Mallorca, Spain
3 Multidisciplinary Sepsis Unit, ICU, Son Llúter University Hospital, 07198, Palma de Mallorca, Spain
4 Immune Response in Human Pathology Group, Health Research Institute of the Balearic Islands (IdISBa), Spain
5 Immunology Department, Son Espases University Hospital, Spain Son Espases University Hospital, 07120, Palma de Mallorca, Spain
6 Infectious Diseases-HIV Group, Health Research Institute of the Balearic Islands (IdISBa), Son Espases University Hospital, 07120, Palma de Mallorca, Spain

**ARTICLE INFO**

**Keywords:** SARS-CoV-2, COVID-19, Paper-based Biosensor, IL-6, Smartphone

**ABSTRACT**

Decentralizing COVID-19 care reduces contagions and affords a better use of hospital resources. We introduce biosensors aimed at detecting severe cases of COVID-19 in decentralized healthcare settings. They consist of a paper immunoassay interfaced with a smartphone. The immunoassays have been designed to generate intense colorimetric signals when the sample contains ultralow concentrations of IL-6, which has been proposed as a prognosis biomarker of COVID-19. This is achieved by combining a paper-based signal amplification mechanism with polymer-filled reservoirs for dispensing antibody-decorated nanoparticles and a bespoke app for color quantification. With this design we achieved a low limit of detection (LOD) of $10^{-3}$ pg mL$^{-1}$ and semiquantitative measurements in a wide dynamic range between $10^{-3}$ and $10^2$ pg mL$^{-1}$ in PBS. The assay time is under 10 min. The low LOD allowed us to dilute blood samples and detect IL-6 with an LOD of 1.3 pg mL$^{-1}$ and a dynamic range up to $10^2$ pg mL$^{-1}$. Following this protocol, we were able to stratify COVID-19 patients according to different blood levels of IL-6. We also report on the detection of IL-6 in respiratory samples (bronchial aspirate, BAS) from COVID-19 patients. The developed test could be easily adapted to detect other cytokines such as TNF-α and IL-8 by changing the antibodies decorating the nanoparticles accordingly. The ability of detecting cytokines in blood and respiratory samples paves the way for monitoring local inflammation in the lungs as well as systemic inflammatory levels in the body.

1. **Introduction**

The SARS-CoV-2 pandemic has rapidly spread worldwide with enormous social and economic repercussions [1]. Patients may be asymptomatic, have mild flu-like symptoms, or progress to severe pneumonia [2]. Previous studies on SARS-CoV and MERS-CoV show that infection of epithelial lung cells provokes a strong local inflammatory response characterized by high levels of cytokines and chemokines [3]. When these pro-inflammatory factors enter the bloodstream they stimulate the release of immature granulocytes in the bone marrow, which exacerbates the inflammation [4]. The resulting hyper-inflammatory syndrome or “cytokine storm” is believed to be

* The Multidisciplinary Sepsis Group comprises a group of clinicians and technology developers devoted to improving sepsis care. The members of the Immune Response in Human Pathology Group study the mechanisms underlying diseases of the immune system. The Infectious Diseases-HIV Group studies clinical aspects of infectious diseases such as Tuberculosis and pneumococcal infections.

**E-mail addresses:** antonio.clemente@ssib.es (A. Clemente), roberto.delarica@ssib.es (R. de la Rica).

1 These authors contributed equally.

https://doi.org/10.1016/j.snb.2020.129333

Received 21 October 2020; Received in revised form 7 December 2020; Accepted 9 December 2020

Available online 14 December 2020

0925-4005/© 2020 Elsevier B.V. All rights reserved.
responsible for many severe cases of COVID-19. IL-6 has been extensively used for prognosticating severe cases of COVID-19. Mild cases show serum IL-6 levels between 5.1 and 18.8 pg mL\(^{-1}\), whereas in moderate/severe cases this value increases to 22.5–198 pg mL\(^{-1}\) \([5–10]\). Stratifying patients according to severity is crucial in order to optimize COVID-19 management. During the first peak of the pandemic, saturation of hospitals forced healthcare providers to decentralize COVID-19 care. Even after “flattening the contagion curve” many mild cases of COVID-19 are cared for at home in order to reduce the risk of contagion \([11]\). Patients with severe symptoms are rapidly transferred to hospitals, where they receive specialized care to prevent poor outcomes. Biosensors for detecting elevated cytokine levels at the point of care could help physicians stratify patients according to their prognosis \([12]\). The challenge in designing such devices is that they would need to be highly portable, easy to manipulate, and require minimal infrastructure to ensure an easy implementation in a decentralized health care strategy \([12, 13]\).

In this manuscript we meet this challenge with mobile biosensors that measure levels of IL-6 in blood and respiratory samples from COVID-19 patients in less than 10 min. In order to meet the urgent need for rapid testing we collated previous discoveries into a new design that meets the needs for decentralized COVID-19 diagnostics. It consists of devices that are entirely made of paper and comprised of two parts: a paper square containing a nanoparticle reservoir and a paper strip for target capture (Fig. 1A). The nanoparticle reservoir is made by adding polystyrene sulfonate (PSS) to a region of the paper. This prevents irreversible interactions between antibody-decorated nanoparticles and the cellulose substrate \([14]\). The reservoir dimensions are defined by a hydrophobic barrier made of paraffin. The paper strip has three capture sites (CS) for amplifying colorimetric signals without adding additional analytical steps \([15]\). To detect IL-6, a drop of sample is added to each capture site and quickly dried. The paper is then folded and soaked with a blocking solution. Subsequently, the reservoir is pressed on top of the folded strip with the aid of a clamp for 5 min (Fig. 1B). During this time, nanoparticles are transferred vertically from the reservoir to the three capture sites (Fig. 1E), where the antibodies recognize IL-6 specifically. After removing the reservoir, a colored spot appears whose pixel intensity is directly related to the concentration of IL-6 in the sample. Since filter paper is semi-transparent when wet, and the biosensors generated a colorimetric signal in each capture site, the colored spot on the folded paper is the sum of the three independent signals generated at each capture site \([15]\). This collective, amplified signal is then quantified with a previously developed smartphone app for densitometry at the point of need \([16]\). The origami-enabled signal amplification mechanism achieves a limit of detection of 10\(^{-3}\) pg mL\(^{-1}\), which is one of the lowest reported to date (Table S1) \([16–39]\). Thanks to this low limit of detection in PBS we were able to dilute patient samples for detecting elevated levels of IL-6 without performing any additional purification steps. This was accomplished in both blood and respiratory samples, thus paving the way for using the proposed biosensors for monitoring systemic and local inflammation. Being able to detect high levels of IL-6 in different biological matrices, along with the rapid turnaround time

![Fig. 1.](image-url)

Photographs of the paper immunosensor and key analytical steps for detecting IL-6; (A) The biosensors consists of a piece of paper containing antibody-decorated nanoparticles, and a paper strip with three capture sites (CS); (B) After adding a drop of sample in each capture site and drying it, the paper is folded; (C) After removing the reservoir, a colored spot appears whose pixel intensity is the sum of the colorimetric signal generated in each capture site; (D) After washing away excess reagents the colorimetric signal is measured with a previously developed smartphone app within seconds; (E) Unfolding the paper strip in (C) reveals that nanoparticles are transferred vertically to the 3 binding sites; (F) Schematic representation of biomolecular interactions; IL-6 is adsorbed onto the paper substrate and subsequently detected by antibody-decorated gold nanoparticles. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
and highly portable detection system, makes our biosensors ideal for the decentralized monitoring of COVID-19 patients both at home and in hospitals.

2. Experimental Section

2.1. Materials

Whatman filter paper #41 and #1 was obtained from GE Healthcare Life Sciences. Wax Paper Squares (6′ ′) was purchased from NORPRO. Gold (III) chloride hydrate, sodium citrate trisodium hydrate, poly (ethylene glycol) 2-mercaptopethyl ether acetic acid (thiol-PEG-acid) 2100, N-Hydroxysulfoaminiscumide sodium salt (sulfo-NHS), N-(3-Dime-thylaminopropyl)-N′-ethylenkarboxidiomid hydrochloride (EDAC; EDC), O-(2-biotinial-aminoethyl) polyethylene glycol 3000 (biotin-PEG), poly (sodium 4-styrenesulfonate, average Mw ≈ 70.000) 30 % solution, Tween-20, 2-ethanesulfonic acid (MES) and recombinant human IL-6 (I2786) were obtained from Sigma Aldrich. Rabbit anti-IL-6 polyclonal antibody (ab6672) was purchased from Abcam. Albumin from bovine serum (BSA, protease free) was obtained from WWR Chemicals. PBS refers to phosphate buffered saline pH 7.4. PBST refers to PBS supplemented with 0.1 % Tween-20. RT refers to room temperature.

2.2. Antibody-decorated gold nanoparticles

Gold nanoparticles with a diameter of ca. 40 nm were obtained with the citrate-reducing method as previously described [16]. The nanoparticles were subsequently modified with antibodies adapting a published protocol. In brief, the citrate around the nanoparticles was substituted for thiol-PEG-acid. Then, the carboxylated moieties were transformed into reactive sulfo-NHS esters via the addition of EDC (1 μM) and sulfo-NHS (2 mg) in 0.5 M MES buffer pH 5.5 for 30 min. Then 200 μL of the nanoparticles were centrifuged at 8000 rpm for 6 min and rabbit anti-IL-6 polyclonal antibody (1 mg mL\(^{-1}\)) was added overnight. Then 200 μL of a blocking solution containing glycine (0.1 M) and BSA (10 mg mL\(^{-1}\)) in phosphate buffer (0.1 M, pH 7.0) was added for at least 30 min to cap any remaining sulfo-NHS ester groups. Subsequently, nanoprobes were washed five times with PBST (6000 rpm, 6 min). Finally, the pellet was resuspended in 100 μL of PBST (AV \(\approx 250\) mM).

2.3. Fabrication of origami biosensors

For the reservoir, Whatman paper #1 was cut into 2 × 2 cm squares, which were then printed with wax with the following procedure. First, wax paper was cut into 2 × 2 cm squares. A 5 × 5 mm circle was removed from the center with a hole puncher. The remaining wax was aligned with the Whatman paper and the paraffin was transferred by pressing a hot iron against it for 5 s. The procedure was repeated on the other side of the paper to completely seal it. Then, a nanoparticle-reservoir was fabricated in the unwaxed paper area by adding 3 μL of 30 % PSS and letting it dry at room temperature (RT) followed by adding 1 μL of antibody-decorated nanoparticles and letting it dry at RT. Paper strips for analyte capture consisted of pieces of Whatman paper #41 cut into 2 × 8 cm strips as shown in Fig. 1A.

2.4. Detection of IL-6

First, 10 μL of sample was added to the first three squares of the paper strip (CS1, 2, and 3 in Fig. 1A) and dried with a hair drier for 30 s. Then, the strip was folded and 1 mL of PBS-BSA was added. Immediately afterwards, the nanoparticle reservoir was placed onto the strip and held with the aid of a clamp for 5 min. The reservoir was then peeled off and the paper strip was washed five times with 1 mL of PBST. The resulting colorimetric signal was measured immediately afterwards with the mobile app [16] Details about the development of the mobile app have been published elsewhere. [16] The app guides the user to establish a controlled distance and angle between the camera of the Huawei POT-LX1 smartphone and the assay by using a virtual frame on the screen that matches the shape of the paper biosensor. After pressing “Set” the app automatically finds the region of interest, calculates the pixel intensity and subtracts it from the background. Uneven light conditions are also automatically corrected. The app stops taking measurements if there are any changes in imaging conditions. This informs the user that the smartphone needs to be realigned, at which point the measurements resume. The data set is evaluated after 50 valid measurements have been acquired. The resulting colorimetric signal S is the highest for black (255) and the lowest for white (0).

Spiked blood samples and bronchial aspirate (BAS) samples were obtained and processed as follows. A blood sample from a healthy donor was spiked with IL-6 by adding 1 μL of a solution 10 times more concentrated to 9 μL of blood. The final concentration of added IL-6 was the one reported in Fig. 3B. The samples were then diluted 1000 times with PBS and tested as above. BAS samples were first liquefied by adding 100 μL of 0.3 M H\(_2\)O\(_2\) to 10 mg of samples for 1 min. The IL-6 concentration of these samples was determined with an in-house ELISA (Fig. S1). A liquefied BAS sample containing less than 3 pg mL\(^{-1}\) IL-6 (below the limit of detection of ELISA) was spiked with the same procedure detailed for blood samples. Samples were diluted 10 times with PBS before applying them to the paper biosensor.

Blood samples from COVID-19 patients were obtained from the Immunology Department at Son Espases University Hospital (Ethics Committee Protocol IB 4169/20 PI). The IL-6 concentration was determined with a DIAsource Immunoassay ELISA kit. Informed consent was obtained from all participants. BAS samples from patients included in this study were provided by Biobank IdISBa and CIBERES Pulmonary Biobank Consortium, a network currently formed by twelve tertiary Spanish hospitals integrated in the Spanish National Biobanks Network. They were processed following standard procedures with the appropriate approval of the Ethics and Scientific Committees and with the collaboration of the healthcare services of the Hospital Universitario Son Espases and Hospital Son Llatzer.

3. Results and discussion

The biosensors shown in Fig. 1 incorporate a signal amplification mechanism based on adding the colorimetric signals generated in multiple capture sites. This concept has already been tested for amplifying signals in paper immunosensors, although not for the detection of IL-6 [15]. To test the impact of implementing this design in the IL-6 biosensors, samples containing 0 or 10 pg mL\(^{-1}\) IL-6 were tested with biosensors modified with nanoparticles at different concentrations. The colorimetric signal was measured with two methods. The first method calculated the pixel intensity only in the capture site CS1. The second method involved folding the paper to measure the collective signal from CS1, CS2 and CS3. Fig. 2A shows scanned images for the resulting assays. As the concentration of gold nanoprobes increased the color in the spot also increased. The color in the folded samples (highlighted in red) was more intense than in the unfolded ones. This is because in the folded sample, the signal from the three capture sites is cumulative [15]. Colored spots were more intense in samples containing IL-6, which indicated that the main contribution to the signal was the specific recognition of IL-6 by antibody-decorated nanoparticles. Fig. 2B summarizes the results obtained after quantifying the color intensity in 3 independent experiments. In this Figure, signals increase when the paper was folded in agreement with the observations in Fig. 2A. In Fig. 2C the specific signal obtained after subtracting the blank from the 10 pg mL\(^{-1}\) sample was plotted as a function of the concentration of nanoprobes. In this plot, the specific signal was always higher when the paper was folded. Furthermore, the standard deviation of three independent experiments was smaller when the paper was folded than when measuring a single capture site. These results confirm that the proposed method enhances specific colorimetric signals in paper immunosensors.
Fig. 2. Colorimetric signal obtained from samples containing 0 or 10 pg mL\(^{-1}\) when using 3 capture sites (CS) and the paper is folded so that the 3 signals add up (red), or unfolded and measuring only CS1 (black); (A) Photographs of the assays; (B) colorimetric signal for 10 (dots) and 0 (squares) pg mL\(^{-1}\); (C) Specific signal after subtracting 0 from 10 pg mL\(^{-1}\). Error bars are the standard deviation (\(n = 3\)). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

without increasing variability. The method only required adding three drops of sample instead of one. No additional reagents or analytical steps were required, making it useful for amplifying signals in rapid diagnostic tests.

After testing the signal amplification mechanism, we calibrated the biosensors with solutions containing different concentrations of recombinant human IL-6 in PBS. In Fig. 3A, the biosensors generated dose-dependent signals that increased linearly with the logarithm of the concentration of IL-6 in the range between 10\(^{-3}\) and 100 pg mL\(^{-1}\). The limit of detection, expressed as the assayed sample that yields a signal above three times the standard deviation of the blank (99% confidence), was 10\(^{-3}\) pg mL\(^{-1}\). This is one of the lowest limits of detection reported for IL-6, and it was achieved with a fast turnaround time under 10 min (Table S1).

However, the proposed biosensors may have a drawback when detecting IL-6 in real matrices. With our device, the analyte is captured by drying the sample in the paper. While this expedites the detection of IL-6, biomolecules such as proteins and mucins present in real matrices may also physically adsorb to the paper and hinder the capture of IL-6. They may also interact non-specifically with the antibody-nanoparticles, interfering with the detection of IL-6. Blood samples are also highly colored, which can be problematic for colorimetric signal generation methods. Fortunately, the biosensors have an exceptionally low limit of detection that allows for the dilution of samples prior to testing, thereby diluting color interferents from the matrix as well. It has been proposed that healthy individuals have IL-6 levels between 0.5 and 6 pg mL\(^{-1}\) [40]. Diluting samples 10\(^3\) times should still enable detecting IL-6 above 6 pg mL\(^{-1}\) (0.006 pg mL\(^{-1}\) in the diluted sample), while reducing matrix effects. With this in mind, we spiked blood samples from a healthy donor with IL-6 in the concentration range between 10 and 100 pg mL\(^{-1}\). Then we diluted these samples 1000 times with PBS and tested them with our biosensors. In Fig. 3B, the biosensor yielded a linear response with the logarithm of the concentration of added IL-6 in the concentration range proposed. These experiments demonstrate that the biosensors can detect IL-6 in blood in the relevant range for COVID-19 care [41]. According to the standard addition method, the basal IL-6 concentration can be estimated in Fig. 3b when \(Y = 0\). This yields a value of 0.6 pg mL\(^{-1}\), which fits well with the IL-6 levels in a healthy individual. The limit of detection obtained by substituting \(S_{\text{blank}} + 3\sigma\) in the linear fitting yields a value of 0.7 pg mL\(^{-1}\). Since this has been added to basal levels in the sample, the final limit of detection in blood is 1.3 pg mL\(^{-1}\). Taking into consideration that the sample was diluted 10\(^3\) times, this limit of detection in blood agrees well with the value obtained in PBS (10\(^{-3}\) pg mL\(^{-1}\), Fig. 3a), which validates our biosensors for detecting abnormal levels of IL-6 (above 6 pg mL\(^{-1}\), highest value for healthy individuals) in blood samples. Finally, we tested whether our biosensors could detect IL-6 in spiked respiratory samples (bronchial aspirate, BAS). To this end, liquefied BAS samples were diluted 10 times with PBS and tested with the same procedure shown above. In Fig. 3C, all samples yield a dose-dependent signal above three times the standard deviation of the matrix signal. These results indicate that our biosensors could be used for monitoring variations in cytokine levels in respiratory samples from COVID-19 patients as well.

Comparison of calibration plots in Fig. 3 reveals that experiments performed in real matrices yield higher sensitivity (higher slope of the calibration plot). That is, the presence of a diluted biologic matrix facilitates the detection of IL-6 compared to the same experiments performed in PBS. The basal concentration of IL-6 in the samples is a constant value added to the concentration spiked into the sample, and therefore cannot be responsible for this increase in sensitivity. We

Fig. 3. Detection of IL-6 in PBS (A), or spiked into blood (B), or bronchial aspirate (BAS, C). Horizontal green dotted lines represent the signal above 3 times the standard deviation of the blank. Error bars are the standard deviation (\(n = 3\)). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
hypothesized that biological components in the matrix that remain in the paper after drying could facilitate antibody-antigen interactions, for example by providing a native environment that preserves IL-6 conformation. The most abundant protein in blood is human serum albumin (HSA), which is present at a concentration of around 40 mg mL\(^{-1}\). To test whether the presence of albumin in the sample could increase the sensitivity of our biosensors, we repeated the calibration experiments, but instead of diluting recombinant IL-6 with PBS we diluted it with PBS supplemented with 40 μg mL\(^{-1}\) bovine serum albumin (BSA). BSA is very similar to HSA in its amino acid composition (76% homology, \([42]\)), and 40 μg mL\(^{-1}\) is the approximate concentration after diluting the sample 10\(^{3}\) times. In Fig. S2, the slope of the calibration plot increases from 11.2 in PBS to 22.4 in PBS-BSA. These experiments demonstrate that the presence of excess proteins in the sample samples the sensitivity of the proposed biosensors. Furthermore, comparison of the same tests measured with the mobile app or via image analysis with ImageJ yielded a higher slope with the app (22.4 vs 16.3), which shows that the quantification method also helps increase the sensitivity of the assay (Fig. S2). To summarize, the high sensitivity and low limit of detection of our tests originate from the paper-based signal amplification mechanism (Fig. 2), the composition of diluted biological matrices (Figs. 3 and S2), and the utilization of a bespoke app for color quantification (Fig. S2). While our tests are semi-quantitative compared to ELISA (Fig. S1) their sensitivity in real matrices may be high enough for detecting high levels of IL-6 in patient samples at the point of care. This is explored below.

Next we tested whether the proposed biosensors could be used for detecting high levels of IL-6 in a panel of blood and BAS samples from patients, which were also analyzed with the gold standard (ELISA) in order to quantify IL-6. In Fig. 4A, patient samples containing IL-6 above 17 pg mL\(^{-1}\) yielded signals statistically different when compared to blood samples from healthy donors (Kruskall-Wallis test, \(p < 0.001\)). This threshold value was in agreement with the cut-off value proposed in the literature to prognosticate severe COVID-19 as well as to guide specific anti-inflammatory treatments \([43,44]\). Fig. 4B summarizes the results obtained from analyzing BAS samples. BAS is usually obtained from intubated patients, and therefore we were not able to compare our results with healthy donors. Instead, we used samples containing IL-6 below 10 pg mL\(^{-1}\) in order to establish a cut-off value. In Fig. 4B, samples containing IL-6 with a concentration of 10 pg mL\(^{-1}\) or higher can be differentiated from those containing undetectable levels by ELISA (Kruskall-Wallis test, \(p < 0.001\)). However, it was not possible to distinguish among samples containing intermediate (10–100 pg mL\(^{-1}\)) and high (above 100 pg mL\(^{-1}\)) levels of IL-6 with the proposed biosensors. To the best of our knowledge no clinical study correlating the levels of IL-6 in respiratory samples with patient severity has yet been published in the context of COVID-19. It should be noted that the decentralized detection of IL-6 in respiratory samples would require sputum rather than BAS, since BAS is usually obtained from intubated patients. While the experiments shown here demonstrate the possibility of measuring IL-6 in samples from the lower respiratory tract, further studies should be performed to determine appropriate cut-off values in sputum samples.

4. Conclusion

In conclusion we have introduced paper immunosensors with a mobile readout platform for the detection of IL-6 in blood and respiratory samples from COVID-19 patients. The immunosensors have a low limit of detection at 10\(^{-3}\) pg mL\(^{-1}\) in PBS. Semi-quantitative measurements can be performed in a wide dynamic range over 5 orders of magnitude due to their paper-based signal generation design. This excellent performance enables diluting real samples to reduce matrix interference. Thanks to this procedure, we were able to correctly classify blood samples from COVID-19 patients with an IL-6 content higher than 17 pg mL\(^{-1}\), and BAS samples above 10 pg mL\(^{-1}\). Higher cut-off values could be set by diluting samples to a larger extent. The biosensors could be adapted to detect other cytokines such as TNF-α and IL-8 by substituting the antibodies around the nanoparticles for others that can recognize these targets specifically. The tests are entirely made of filter paper, which makes them lightweight, easy to transport and distribute, and easy to dispose of by incineration. Our app does not require any lightbox or accessory to control photographic conditions, making it particularly useful for home testing. These features, along with the ability to identify patients with elevated IL-6 levels at low cut-off values, makes the proposed biosensors a promising tool for the decentralized management of COVID-19 patients at home or in hospitals.

Competing interests statement

A patent application describing the method for storing nanoparticles in paper reservoirs has been filed (PCT/EP2020/075013). A patent application describing the method for liquefying respiratory samples has also been filed (P202030403).

CRediT authorship contribution statement

Cristina Adrover-Jaume: Investigation, Validation, Writing - review & editing. Alejandra Alba-Patiño: Investigation, Validation, Writing - review & editing. Antonio Clemente: Investigation, Data curation, Conceptualization, Supervision, Writing - review & editing. Giulia Santopolo: Investigation, Writing - review & editing. Andreu Vaquer: Investigation, Writing - review & editing. Steven M. Russell: Software, Visualization, Writing - review & editing. Enrique Barón: Investigation, Writing - review & editing. María del Mar González del Campo: Investigation, Writing - review & editing. Joana M. Ferrer: Investigation, Writing - review & editing. Maria Berman-Riu: Investigation, Writing - review & editing. Mercedes García-Gasalla: Investigation, Writing - review & editing. María Aranda: Investigation. Marcio Borges: Investigation, Writing - review & editing. Roberto de la Rica: Conceptualization, Project administration, Supervision, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

The authors report no declarations of interest.
Acknowledgments

R.R acknowledges financial support from grants FEDER/Ministerio de Ciencia, Innovación y Universidades/Agenida Estatal de Investigación/- ProyectoCTQ2017-82432-R and FEDER/Ministerio de Ciencia, Innovación y Universidades/Agenida Estatal de Investigación/- ProyectoCTQ2017-92226-EXP. Radix (R.R.), Foilum (A.C., M.G) and Talent + fellowships from IdISBa/Impost turisme sostenible / Agència Estratègica Turística de les Illes Balears-Govern de les Illes Balears are reported. A.A. acknowledges a fellowship for doctoral studies from Roche (“Stop fuga de cerebros” program). E.B. acknowledges funding from the Instituto de Salud Carlos III (Sara Borrell contract). M.G.-G. acknowledges funding from Instituto de Salud Carlos III (project COV20/00943). We want to particularly acknowledge the patients, Biobank IdISBa and CIBERES Pulmonary Biobank Consortium (PT17/0015/0001) member of the Spanish National Biobanks Network financed by the Carlos III Health Institute, with the participation of the Units of Intensive Care, Clinical Analysis and Pulmonology of Hospital Universitari Son Espases and Hospital Son Llàtzer, for their collaboration.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:10.1016/j.snb.2020.129333.

References

[1] A. Karami, M. Hasani, F.A. Jalilian, R.B. Polidoro, R.S. Hagan, R. de Santis Santiago, N.W. Schmidt, Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection, Front. Immunol. 11 (2020), https://doi.org/10.3389/fimmu.2020.01855.
[2] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, H. Han, Q. Ma, C. Li, R. Liu, L. Zhao, W. Wang, P. Zhang, X. Liu, G. Gao, F. Liu, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506. https://doi.org/10.1016/S0140-6736(20)30182-X.
[3] R. Zhangapanavar, S. Perlman, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin. Immunopathol. 39 (2017) 529–539. https://doi.org/10.1007/s00295-017-0629-z.
[4] R.B. Polidoro, R.S. Hagan, R. de Santis Santiago, N.W. Schmidt, Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19, Front. Immunol. 11 (2020). https://doi.org/10.3389/fimmu.2020.01855.
[5] Q. Cai, D. Huang, P. Ou, H. Yu, Z. Zhu, Z. Xia, Y. Su, Z. Ma, Y. Zhang, Z. Li, Q. He, L. Liu, Y. Fu, J. Chen, COVID-19 in a designated infectious diseases hospital outside Hubei Province, China, Allergy Eur. J. Allergy Clin. Immunol. 75 (2020) 1743–1752. https://doi.org/10.1111/eaa.13701.
[6] G. Chen, D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, Xiaoyun Zhang, H. Chen, H. Yu, Xiaoping Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S. Li, X. Luo, J. Zhao, Q. Ning, Clinical and immunological features of severe and moderate coronavirus disease 2019, J. Clin. Invest. (2020). https://doi.org/10.1172/JCI137244.
[7] H. Han, Q. Ma, C. Li, R. Liu, L. Zhao, W. Wang, P. Zhang, X. Liu, G. Gao, F. Liu, Y. Jiang, X. Cheng, Z. Xu, Z. Xia, Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease predictor, Emerg. Microbes Infect. 9 (2020) 1125–1130. https://doi.org/10.1080/22221751.2020.1771297.
[8] J.S. Kwon, J.Y. Kim, M.-C. Kim, S.Y. Park, B.-N. Kim, S. Bae, H.H. Cha, J. Jung, M.-J. Kim, M.J. Lee, S.-H. Choi, J.W. Chung, E.C. Shin, H.-S. Kim, Factors of severity in patients with COVID-19: cytokine/cytokine concentrations, viral load, and antibody responses, Am. J. Trop. Med. Hyg. 100 (2020) 2412–2418. https://doi.org/10.4269/ajtmh.20-1110.
[9] C. Maucourant, I. Filipovic, A. Ponzetta, S. Aleman, M. Cornellet, L. Hertwig, B. Sartori, A. Lenti, B. Reinus, D. Brownlee, A. Guipiz, E.H. Ask, R.M. Hult, A. Haroun-Izquierdo, M. Schaffer, J. Klingstein, E. Fokkens, M. Buggert, K.J. Sandberg, L.L. Eriksson, O. Rooyackers, H.G. Ljunggren, K.J. Malmberg, J. Michaelsson, N. Marquardt, Q. Hammer, K. Strålin, N.K. Bjorkstrom, Natural killer cell immunotypes related to COVID-19 disease severity, Sci. Immunol. 5 (2020) eabc6832. https://doi.org/10.1126/scimimunol.abc6832.
[10] H. Wang, S. Luo, Y. Shen, M. Li, Z. Zhang, Y. Dong, H. Zhou, L. Lin, W. Guo, Z. Kang, L. Xing, J. Li, H. Ye, W. Gai, Y. Hu, M. Yuan, S. Han, R. Zhu, Y. Ye, Y. Wang, X. Jiang, H. Zhao, X. Zheng, H. Fan, L. Zhang, Y. Hu, D. Hu, Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-center, correlated study with CT imaging score, Lancet Infect. Dis. (2020). https://doi.org/10.1016/S1473-3099(20)30483-7.
interleukin-6 in unprocessed whole blood, Biosens. Bioelectron. 141 (2019), 111432, https://doi.org/10.1016/j.bios.2019.111432.

[35] H. Wei, S. Ni, C. Cao, G. Yang, G. Liu, Graphene oxide signal reporter based multifunctional immunosensing platform for amperometric profiling of multiple cytokines in serum, ACS Sens. 3 (2018) 1553–1561, https://doi.org/10.1021/acs.sens.8b00365.

[36] J. Wu, Y. Chen, Mingzhu Yang, Y. Wang, C. Zhang, Mo Yang, J. Sun, M. Xie, X. Jiang, Streptavidin-biotin-peroxidase nanocomplex-amplified microfluidics immunosassays for simultaneous detection of inflammatory biomarkers, Anal. Chim. Acta 982 (2017) 138–147, https://doi.org/10.1016/j.aca.2017.05.031.

[37] B. Yin, W. Zheng, M. Dong, W. Yu, Y. Chen, S.W. Joo, X. Jiang, An enzyme-mediated competitive colorimetric sensor based on Au@Ag bimetallic nanoparticles for highly sensitive detection of disease biomarkers, Analyst 142 (2017) 2954–2960, https://doi.org/10.1039/c7an00779c.

[38] K. Zhang, G. Liu, E.M. Goldys, Robust immunosensing system based on biotin-streptavidin coupling for spatially localized femtogram mL–1 level detection of interleukin-6, Biosens. Bioelectron. 102 (2018) 80–86, https://doi.org/10.1016/j.bios.2017.11.023.

[39] J. Zhu, J. He, M. Verano, A.T. Brimmo, A. Glia, M.A. Qasaimeh, F. Chen, J. O. Aleman, W. Chen, An integrated adipose-tissue-on-chip nanoplasmonic biosensing platform for investigating obesity-associated inflammation, Lab Chip 18 (2018) 3550–3560, https://doi.org/10.1039/c8lc00605a.

[40] H.J. Seo, K.K. Park, S.S. Han, W.Y. Chung, M.W. Son, W.B. Kim, Y.J. Surh, Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis, Int. J. Cancer 100 (2002) 463–471, https://doi.org/10.1002/ijc.10496.

[41] D.M. Del Valle, S. Kim-Schulze, H.H. Huang, N.D. Beckmann, S. Nirenberg, B. Wang, Y. Lavin, T.H. Swartz, D. Maddahi, A. Stock, T.U. Marron, H. Xie, M. Patel, K. Tuballes, O. Van Oerkelen, A. Rahman, P. Kovatch, J.A. Aberg, E. Schadt, S. Jagannath, M. Mazumdar, A.W. Charney, A. Firpo-Betancourt, D. R. Mendu, J. Zhang, D. Reich, K. Sigel, C. Cordon-Cardo, M. Feldmann, S. Parekh, M. Merad, S. Gnajtis, An inflammatory cytokine signature predicts COVID-19 severity and survival, Nat. Med. 26 (2020) 1636–1643, https://doi.org/10.1038/s41591-020-1051-9.

[42] B.X. Huang, H.-Y. Kim, C. Dass, Probing three-dimensional structure of bovine serum albumin by chemical cross-linking and mass spectrometry, J. Am. Soc. Mass Spectrom. 15 (2004) 1237–1247, https://doi.org/10.1016/j.jasms.2004.05.004.

[43] B. Fu, X. Xu, H. Wei, Why tocilizumab could be an effective treatment for severe COVID-19? J. Transl. Med. 18 (2020) 164, https://doi.org/10.1186/s12967-020-02339-3.

[44] P. Luo, Y. Liu, L. Qiu, X. Liu, D. Liu, J. Li, Tocilizumab treatment in COVID-19: a single center experience, J. Med. Virol. (2020), https://doi.org/10.1002/jmv.25801.